User profiles for Jordan J. Feld
Jordan FeldProfessor of Medicine, Toronto Centre for Liver Disease, University Health Network … Verified email at uhn.ca Cited by 31570 |
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis
AJ Van Der Meer, BJ Veldt, JJ Feld, H Wedemeyer… - Jama, 2012 - jamanetwork.com
… Dr Feld reported receiving financial compensation for consultancy, lecture, and development
of educational presentation activities from Hoffmann-LaRoche, Merck, Gilead, Tibotec, …
of educational presentation activities from Hoffmann-LaRoche, Merck, Gilead, Tibotec, …
Mechanism of action of interferon and ribavirin in treatment of hepatitis C
JJ Feld, JH Hoofnagle - Nature, 2005 - nature.com
Since the identification of the hepatitis C virus, great strides have been made in the development
of an antiviral therapy. As a crucial mediator of the innate antiviral immune response, …
of an antiviral therapy. As a crucial mediator of the innate antiviral immune response, …
[HTML][HTML] Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection
JJ Feld, IM Jacobson, C Hézode… - … England Journal of …, 2015 - Mass Medical Soc
Background A simple treatment regimen that is effective in a broad range of patients who
are chronically infected with the hepatitis C virus (HCV) remains an unmet medical need. …
are chronically infected with the hepatitis C virus (HCV) remains an unmet medical need. …
[HTML][HTML] Treatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin
Background The interferon-free combination of the protease inhibitor ABT-450 with ritonavir
(ABT-450/r) and the NS5A inhibitor ombitasvir (also known as ABT-267) plus the …
(ABT-450/r) and the NS5A inhibitor ombitasvir (also known as ABT-267) plus the …
[HTML][HTML] Residual NADPH oxidase and survival in chronic granulomatous disease
Background Failure to generate phagocyte-derived superoxide and related reactive oxygen
intermediates (ROIs) is the major defect in chronic granulomatous disease, causing …
intermediates (ROIs) is the major defect in chronic granulomatous disease, causing …
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
…, H Cheinquer, G Dusheiko, JJ Feld… - The lancet …, 2019 - thelancet.com
Viral hepatitis is a major public health threat and a leading cause of death worldwide. Annual
mortality from viral hepatitis is similar to that of other major infectious diseases such as HIV …
mortality from viral hepatitis is similar to that of other major infectious diseases such as HIV …
[HTML][HTML] Glecaprevir–pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection
…, S Wang, A Asatryan, E Gane, JJ Feld… - … England Journal of …, 2018 - Mass Medical Soc
Background Glecaprevir and pibrentasvir are direct-acting antiviral agents with pangenotypic
activity and a high barrier to resistance. We evaluated the efficacy and safety of 8-week …
activity and a high barrier to resistance. We evaluated the efficacy and safety of 8-week …
Extrahepatic morbidity and mortality of chronic hepatitis C
Chronic hepatitis C virus (HCV) infection is associated with several extrahepatic manifestations.
Patients with HCV may develop mixed cryoglobulinemia and its sequelae, ranging from …
Patients with HCV may develop mixed cryoglobulinemia and its sequelae, ranging from …
[PDF][PDF] Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome
JJ Feld, H Dinh, T Arenovich, VA Marcus… - …, 2005 - Wiley Online Library
Although the natural history of autoimmune hepatitis (AIH) has been characterized, little is
known about patients who present asymptomatically. Consequently, whether they require …
known about patients who present asymptomatically. Consequently, whether they require …
[HTML][HTML] From non-A, non-B hepatitis to hepatitis C virus cure
JM Pawlotsky, JJ Feld, S Zeuzem, JH Hoofnagle - Journal of hepatology, 2015 - Elsevier
… Although I am not as young as Jordan Feld, I still hope I will also see the real fruits of all of
… Jordan J. Feld has received research grants from Abbvie, Boehringer-Ingelheim, Gilead …
… Jordan J. Feld has received research grants from Abbvie, Boehringer-Ingelheim, Gilead …